By integrating molecular barcoding technology with the Blocker Displacement Amplification (BDA) allele enrichment, the team invented the new quantitative BDA (QBDA) method that overcomes potential biases in BDA to enable accurate VAF quantitation.
The deal will combine C2i’s AI-driven cancer intelligence platform with NuProbe’s advanced sequencing technology to power pharma and diagnostic services.
OCEANS enables rapid, accurate, and affordable detection of somatic mutations as low as 0.05% VAF. This novel research will facilitate the development of same-day, low-cost oncology panels for time-sensitive therapy selection and recurrence monitoring.
NuProbe will integrate QASeq and BDA technologies with Bionano’s Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.
NuProbe published research on DNA microsatellites in Nucleic Acids Research and released VarTrace® MSI qPCR research use only assay.
The findings, published in Nature Communications, are the latest research leveraging machine learning to improving the efficiency and accuracy of genomics. The study was co-authored by researchers from NuProbe USA, Rice University, and Microsoft Research UK.
Research published in Nature Biomedical Engineering demonstrates NuProbe’s technology can enable detecting SNVs in DNA with a VAF of ≤0.02% using a sequencing depth of only 250x.
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
NuProbe launches the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™ will procedurally generate NGS panels for cell-free DNA (cfDNA) analysis, covering the entire coding regions of between 1 and 30 genes of interest.